Y. Koh

Yukiko Nakamura, F. Tanaka, M. Endo, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.

S. Akinaga, K. Muro, Y. Koh, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.

Yukiko Nakamura, T. Nakajima, M. Endo, 2011, Lung cancer.

Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells

Y. Koh, H. Murakami, Toshiaki Takahashi, 2014, Cancer science.

Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells.

K. Yamaguchi, M. Kusuhara, Y. Koh, 2014, Anticancer research.

Osimertinib With Ramucirumab in EGFR‐mutated, T790M‐positive Patients With Progression During EGFR‐TKI Therapy: Phase Ib Study

Y. Koh, N. Yamamoto, Y. Ozawa, 2018, Clinical lung cancer.

Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients

Y. Koh, N. Yamamoto, H. Akamatsu, 2017, PloS one.

Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.

Y. Koh, N. Yamamoto, H. Akamatsu, 2019, Clinical lung cancer.

Drug resistance in lung cancer.

N. Saijo, K. Nishio, H. Fukumoto, 1999, Current opinion in oncology.

High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter

Y. Koh, Y. Ozawa, N. Tokudome, 2021, AntiCancer Research.

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients

M. Taniwaki, S. Iida, J. Liao, 2021, International Journal of Hematology.

Design, Synthesis, Protein-ligand X-ray Structures and Biological Evaluation of a Series of Novel Macrocyclic HIV-1 Protease Inhibitors to Combat Drug-resistance

David D. Anderson, Arun K. Ghosh, I. Weber, 2010 .

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer

C. Kitagawa, M. Ando, A. Kubo, 2022, BMC Cancer.

Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis.

N. Saijo, K. Nishio, H. Yamaue, 2003, International journal of oncology.

Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations.

Ayaka Tanaka, Y. Koh, N. Yamamoto, 2015, The journal of allergy and clinical immunology. In practice.

The effect of CYP 2 C 19 polymorphism on the safety , tolerability , and pharmacokinetics of tivantinib ( ARQ 197 ) : results from a phase I trial in advanced solid tumors

S. Akinaga, K. Muro, Y. Koh, 2013 .

In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

N. Saijo, K. Nishio, H. Fukumoto, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Is response rate or stable disease rate a surrogate endpoint for survival in the treatment of advanced non-small cell lung cancer using epidermal growth factor receptor tyrosine kinase inhibitors?

A. Kubo, M. Takada, Y. Koh, 2008 .

Nivolumab induced radiation recall pneumonitis after two years of radiotherapy.

Y. Koh, N. Yamamoto, H. Akamatsu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.

Arun K. Ghosh, H. Mitsuya, Y. Koh, 2009, Biological & pharmaceutical bulletin.

Molecular determinants of UCN‐01‐induced growth inhibition in human lung cancer cells

J. Usuda, H. Kato, N. Saijo, 2000, International journal of cancer.

Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes

C. Kitagawa, M. Ando, A. Kubo, 2022, BMC Cancer.

Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition

H. Mitsuya, Y. Koh, H. Bulut, 2019, Scientific Reports.

Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors.

H. Mitsuya, N. Fujii, Y. Koh, 2004, The Journal of organic chemistry.

Bis‐Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance

Arun K. Ghosh, Hiroaki Mitsuya, I. Weber, 2006, ChemMedChem.

Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

Arun K. Ghosh, D. Walters, H. Mitsuya, 2005, Journal of medicinal chemistry.

Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.

H. Mitsuya, K. Maeda, A. Otaka, 2003, Journal of medicinal chemistry.

Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.

David D. Anderson, Heather B. Miller, Arun K. Ghosh, 2009, Journal of medicinal chemistry.

Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P′2-ligands

Arun K. Ghosh, D. Walters, H. Mitsuya, 2006 .

Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells.

J. Park, S. Um, Y. Koh, 2001, Cancer letters.

Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

Arun K. Ghosh, D. Walters, H. Mitsuya, 2011, Journal of medicinal chemistry.

Activity against Human Immunodeﬁciency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4 (cid:2) -Ethynyl-2-Fluoro-2 (cid:2) -Deoxyadenosine (cid:1)

Christopher M. Bailey, M. Matsuoka, H. Mitsuya, 2007 .

A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multiple-PI-Resistant Human Immunodeficiency Virus In Vitro

Irene T Weber, Masayuki Amano, Yuan-Fang Wang, 2007, Antimicrobial Agents and Chemotherapy.

Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Arun K. Ghosh, J. Wedekind, I. Weber, 2006, Journal of medicinal chemistry.

Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir

Arun K. Ghosh, H. Mitsuya, Y. Koh, 2014, Proceedings of the National Academy of Sciences.

Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization*

Masayuki Amano, Debananda Das, Arun K. Ghosh, 2007, Journal of Biological Chemistry.

The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues.

Takashi Nakajima, Hirofumi Yasui, T. Nakajima, 2015, Cancer genetics.

Combined Treatment with Erlotinib and a Transforming Growth Factor-&bgr; Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells

Y. Koh, Toshiaki Takahashi, N. Yamamoto, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.

Y. Koh, N. Yamamoto, Y. Ozawa, 2021, Clinical lung cancer.

Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy.

Y. Koh, Yoshiya Matsumoto, 2020, Immunotherapy.

PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue

Y. Koh, M. Serizawa, K. Kusafuka, 2018, BMC Cancer.

PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue

T. Sugiyama, Y. Koh, M. Serizawa, 2018, BMC Cancer.

Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1

Dana M. Brantley-Sieders, M. Sanders, H. Moses, 2003, Molecular and Cellular Biology.

Impact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study

H. Saka, M. Ando, A. Kubo, 2020, Cancer medicine.

PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.

H. Saka, A. Kubo, H. Wanibuchi, 2017, Lung cancer.

Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.

T. Nakajima, M. Endo, Y. Koh, 2016, Lung cancer.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

H. Mukai, Y. Ohashi, K. Nishio, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 3993: A microarray-based gene expression analysis identified diagnostic biomarkers for unknown primary cancer

K. Nishio, Y. Koh, K. Nakagawa, 2014 .

Conditional Overexpression of Active Transforming Growth Factor β1 In vivo Accelerates Metastases of Transgenic Mammary Tumors

L. Chodosh, M. Barcellos-Hoff, S. Moody, 2004, Cancer Research.

Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility*

C. Arteaga, N. Dumont, Y. Koh, 2004, Journal of Biological Chemistry.

Correlation of Recombinant Integrase Activity and Functional Preintegration Complex Formation during Acute Infection by Replication-Defective Integrase Mutant Human Immunodeficiency Virus

A. Engelman, Y. Koh, X. Li, 2012, Journal of Virology.

Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single‐institute study

T. Nakajima, M. Endo, Y. Koh, 2014, Cancer.

A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer

Yuichi Takiguchi, Hirofumi Mukai, Nobuyuki Yamamoto, 2013, PloS one.

Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.

A. Kubo, M. Kitaichi, M. Takada, 2011, Internal medicine.

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

Fumiaki Koizumi, N. Saijo, K. Nishio, 2004, Cancer science.

Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells

Y. Koh, N. Yamamoto, M. Serizawa, 2020, AntiCancer Research.

Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

K. Hirata, Tatsuo Kimura, Y. Koh, 2019, Lung cancer.

Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation

A. Engelman, Y. Koh, M. Kvaratskhelia, 2013, Proceedings of the National Academy of Sciences.

Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).

E. Baba, N. Sugimoto, I. Hyodo, 2020, European journal of cancer.

Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells.

Y. Koh, Toshiaki Takahashi, N. Yamamoto, 2013, Anticancer research.

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter

T. Nakajima, M. Endo, Y. Koh, 2018, Cancer science.

Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.

T. Nakajima, M. Endo, Y. Koh, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR‐mutant non‐small cell lung cancer

Tatsuo Kimura, Y. Koh, N. Yamamoto, 2019, Cancer science.

Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays

T. Nakajima, M. Endo, Y. Koh, 2014, BMC Cancer.

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

S. Morita, Y. Koh, I. Okamoto, 2020, BMC Cancer.

Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan

H. Saka, M. Ando, A. Kubo, 2020, BMJ Open.

Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells

M. Yunokawa, K. Tamura, Y. Koh, 2016, Cancer science.

Biology of Human Tumors UltraSensitive Detection of the Pretreatment EGFR T 790 M Mutation in Non – Small Cell Lung Cancer Patientswith anEGFR-ActivatingMutation Using Droplet Digital PCR

Y. Ichinose, H. Saka, M. Ando, 2015 .

Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR

Y. Ichinose, H. Saka, M. Ando, 2017, EBioMedicine.

Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patientswith anEGFR-ActivatingMutation Using Droplet Digital PCR

Y. Ichinose, H. Saka, M. Ando, 2015 .

Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.

T. Nakajima, M. Endo, M. Kusuhara, 2017, Lung cancer.

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

T. Nakajima, M. Endo, Kazuhisa Takahashi, 2016, BMC Cancer.

Molecular profiling of small cell lung cancer in a Japanese cohort.

T. Nakajima, M. Endo, Y. Koh, 2014, Lung cancer.

The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Recieved Concurrent Chemoradiotherapy

Masahiro Endo, Takashi Nakajima, Akira Ono, 2014, American journal of clinical oncology.

Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors*

A. Engelman, S. L. Le Grice, Y. Koh, 2012, The Journal of Biological Chemistry.

The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors*

A. Engelman, H. Mitsuya, Y. Koh, 2013, The Journal of Biological Chemistry.

A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood

Y. Koh, Toshiaki Takahashi, N. Yamamoto, 2014, Journal of Translational Medicine.

GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 In Vitro

Arun K. Ghosh, H. Mitsuya, M. Nakayama, 2008, Antimicrobial Agents and Chemotherapy.

Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.

Y. Koh, N. Yamamoto, H. Akamatsu, 2019, Lung cancer.

Y. Koh, N. Yamamoto, Y. Ozawa, 2019, The oncologist.

Characteristics of lung cancer in Korea, 1997.

Y. Koh, J. S. Song, K. Yoo, 2000, Lung cancer.

Identification and Characterization of Persistent Intracellular Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitor Activity

A. Engelman, Y. Koh, H. Haim, 2010, Antimicrobial Agents and Chemotherapy.

Identification and characterization of persistent intracellular human 1 immunodeficiency virus type 1 integrase strand transfer inhibitor activity 2 3 4

A. Engelman, Y. Koh, H. Haim, 2010 .

Identification of actionable mutations in malignant pleural mesothelioma.

T. Nakajima, M. Endo, Y. Koh, 2014, Lung cancer.

Halogenated thymidine analogues restore the expression of silenced genes without demethylation.

M. Nakao, M. Matsuoka, Jun Fan, 2005, Cancer research.

Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers.

N. Saijo, K. Nishio, H. Fukumoto, 2002, Experimental biology and medicine.

The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer.

A. Kubo, Y. Koh, H. Kaneda, 2022, Clinical lung cancer.

Y. Koh, N. Yamamoto, Y. Ozawa, 2019, The oncologist.

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.

Y. Koh, N. Yamamoto, H. Akamatsu, 2018, Lung cancer.

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.

Hiroaki Mitsuya, H. Mitsuya, K. Maeda, 2004, Current opinion in pharmacology.

Differential Effects of Human Immunodeficiency Virus Type 1 Capsid and Cellular Factors Nucleoporin 153 and LEDGF/p75 on the Efficiency and Specificity of Viral DNA Integration

Kenneth A. Matreyek, A. Engelman, S. Hughes, 2012, Journal of Virology.

Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors

Hiroaki Mitsuya, Kazuhisa Yoshimura, D. Venzon, 2009, Journal of Virology.

Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer.

Nobuyuki Yamamoto, Ryo Negishi, Tomoko Yoshino, 2013, Analytical chemistry.

MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma

T. Nakajima, Y. Koh, K. Kaira, 2011, Virchows Archiv.

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50

Y. Koh, N. Yamamoto, J. Fukuoka, 2020, Cancer science.

Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and &bgr; III-Tubulin in Thymic Epithelial Tumors

T. Nakajima, M. Endo, Y. Koh, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

Y. Koh, N. Yamamoto, Y. Ozawa, 2020, Cancer medicine.

Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1

Arun K. Ghosh, R. Shafer, H. Mitsuya, 2011, Journal of Virology.

Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).

M. Ando, Y. Koh, A. Tamiya, 2020, Clinical lung cancer.

HIV-1 Integrase Inhibitors Primary Mechanism of Action of Allosteric Aberrant Protein Multimerization as the The A 128 T Resistance Mutation Reveals Molecular Bases of Disease :

A. Engelman, H. Mitsuya, Y. Koh, 2013 .

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Yutaka Suzuki, T. Yamanaka, S. Nomura, 2017, British Journal of Cancer.

T. Yamanaka, S. Nomura, H. Esumi, 2017, British Journal of Cancer.

Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations

Y. Koh, N. Yamamoto, H. Kaneda, 2021, Translational oncology.

High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood

Toru Futami, Nobuyuki Yamamoto, Takeshi Sawada, 2015, PloS one.

Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro

H. Mitsuya, K. Maeda, Y. Koh, 2004, Journal of Virology.

In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors

Arun K. Ghosh, H. Mitsuya, M. Nakayama, 2010, Journal of Virology.

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

K. Azuma, Y. Koh, N. Yamamoto, 2023, BMC Cancer.

Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing.

T. Nakajima, M. Endo, Y. Koh, 2017, Clinical lung cancer.

Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors

Y. Koh, N. Yamamoto, H. Kaneda, 2021, Scientific Reports.

Polymorphic LEDGF/p75 variants support efficient HIV-1 infection ex vivo.

A. Engelman, Y. Koh, E. Ballana, 2013, AIDS.

P2.07-035 Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab

Y. Koh, N. Yamamoto, H. Akamatsu, 2017 .

Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells

N. Saijo, Y. Koh, T. Tamura, 2001, Cancer.

Gene Expression Profiling of Exposure to TZT-1027, a Novel Microtubule-Interfering Agent, in Non-Small Cell Lung Cancer PC-14 Cells and Astrocytes

N. Saijo, K. Nishio, T. Natsume, 2004, Investigational New Drugs.

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Yutaka Suzuki, T. Yamanaka, S. Nomura, 2019, Biomedical reports.

Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).

Y. Koh, N. Yamamoto, S. Takamori, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prediction of Potency of Protease Inhibitors Using Free Energy Simulations with Polarizable Quantum Mechanics-Based Ligand Charges and a Hybrid Water Model

Yasushi Tojo, Debananda Das, Yasuhiro Koh, 2009, J. Chem. Inf. Model..

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant

S. Nomura, S. Mimaki, K. Matsushima, 2023, International Journal of Clinical Oncology.

Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors

Takanori Yoshikawa, Y. Koh, Y. Ozawa, 2022, Cancer Immunology, Immunotherapy.

Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib

A. Kubo, M. Takada, Y. Koh, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunodeficiency Virus In Vitro against Multi-PI-Resistant Human UIC-94017 ( TMC 114 ) with Potent Activity Nonpeptidic Protease Inhibitor ( PI )-Tetrahydrofuranylurethane-Containing bis Novel

Irene T. Weber, Robert W. Harrison, Patra Volarath, 2003 .

Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.

David D. Anderson, Arun K. Ghosh, I. Weber, 2009, Journal of medicinal chemistry.

Loss of the Protease Dimerization Inhibition Activity of Tipranavir (TPV) and Its Association with the Acquisition of Resistance to TPV by HIV-1

H. Mitsuya, Y. Koh, M. Danish, 2012, Journal of Virology.

Prediction of Potency of Protease Inhibitors Using Free Energy Simulations with Polarizable Quantum Mechanics‐Based Ligand Charges and a Hybrid Water Model.

Yasushi Tojo, Debananda Das, Arun K. Ghosh, 2010 .

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519

N. Saijo, K. Nishio, Takashi Nakamura, 2001, Japanese journal of cancer research : Gann.

O2-7-3Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Y. Koh, N. Yamamoto, H. Akamatsu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency department

Y. Koh, N. Yamamoto, Y. Ozawa, 2021, Acute medicine & surgery.

Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion

T. Nakajima, M. Endo, Y. Koh, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel HIV-1 Protease Inhibitors (PIs) Containing a Bicyclic P2 Functional Moiety, Tetrahydropyrano-Tetrahydrofuran, That Are Potent against Multi-PI-Resistant HIV-1 Variants

Arun K. Ghosh, H. Mitsuya, Y. Koh, 2011, Antimicrobial Agents and Chemotherapy.

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).

K. Azuma, Y. Koh, N. Yamamoto, 2023, Journal of Clinical Oncology.

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

Jason J. Z. Liao, H. Iwasaki, S. Iida, 2020, International Journal of Hematology.